Molecular targeted therapy is a hot topic of research in oncology in recent years, and its aim is to minimize the systemic adverse effects of patients throughout the treatment process through precise treatment of tumors. The aim is to minimize the systemic adverse effects during the whole treatment process by precisely treating the tumor, so that the treatment can maximize the effect and minimize the adverse effects. Dozens of targeted therapeutic agents have been introduced into clinical use, and there are two main categories of these drugs, monoclonal antibodies and small molecule compounds. Small-molecule compounds, either chemically synthesized or extracted and screened from natural sources, can act on one or more key proteins that regulate tumor growth, thus blocking the signaling pathways for tumor growth to treat tumors. Our study identified a small molecule compound called perifosine that has a significant killing effect on non-small cell lung cancer cells and may facilitate the treatment of clinical lung cancer in the future. The results of this study were published in the official journal of the American Association for Cancer Research
Molecular Cancer Therapeutics 2007;6:2029-38 entitled: The alkylphospholipid
perifosine induces apoptosis of human lung cancer cells requiring inhibition of
Akt and activation of the extrinsic apoptotic pathway.